S&P 500   5,051.41 (-0.21%)
DOW   37,798.97 (+0.17%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
S&P 500   5,051.41 (-0.21%)
DOW   37,798.97 (+0.17%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
S&P 500   5,051.41 (-0.21%)
DOW   37,798.97 (+0.17%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
S&P 500   5,051.41 (-0.21%)
DOW   37,798.97 (+0.17%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
Free Trial

Denali Therapeutics (DNLI) ESG Score & Sustainability Data

→ Can't believe it's happening again (From Manward Press) (Ad)
Free DNLI Stock Alerts
$17.34
-0.50 (-2.80%)
(As of 04:00 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Key ESG Takeaways for Denali Therapeutics

The key takeaways are AI-generated and highlight the main contributors behind the net impact scores of Denali Therapeutics. The insights are based on millions of scientific articles, along with the company-specific product and service portfolio.
  • Denali Therapeutics seems to create the most significant positive value in categories , , and . The largest positive contribution comes from its impact, which is mostly driven by its Clinical research services for physiological diseases , Basic medical research services, and Preclinical research services for physical health products.
  • On the other hand, these positive outcomes are achieved by using resources or causing negative impacts in categories , , and . The negative contribution in the impact category seems to be driven mostly by its Clinical research services for infectious diseases, Clinical research services for physiological diseases , and Clinical research services for genetic diseases products.
  • To improve its net impact, a company can either grow its positive impacts, or reduce its negative impacts. For example, by doubling its Preclinical research services for physical health business, Denali Therapeutics would improve its net impact ratio by 1 percentage points.

DNLI Impact Ratio

Net impact ratio represents the net impact of a company. It is defined as the (positive impacts - negative impacts) / positive impacts. The maximum value for net impact ratio is 100%, representing a theoretical company with no negative impacts. The minimum value is -∞. Net scores depend on the value sets that determine the importance of different impact categories.
+74.5%
The default value set, where each category is given the same weight.

Value Sets Value sets can be used to assess how different stakeholder values or emphasis on certain values might affect the net impact ratio.

Millennials
Value set of millennials (b. 1980 - 1999), based on Upright's annual Impact at Work survey.
+78.8%
Most Wanted Workforce
Value set of the most wanted workforce, based on Upright's annual Impact at Work survey.
+71.5%
Society First
Value set that emphasizes society impacts over other impacts.
+56.8%
Knowledge First
Value set that emphasizes knowledge impacts over other impacts.
+91.0%
Health First
Value set that emphasizes health impacts over other impacts.
+81.3%

Denali Therapeutics ESG Score + Net Impact Profile

ImpactNegativeScorePositive
+2.48
+2.48
+1.91
+1.91
+0.00
+0.00
-0.01
+0.02
+0.03
-0.09
+0.06
+0.16
0.00
+0.00
+6.04
+6.04
-0.00
0.00
+0.00
-2.33
-2.33
-0.55
+3.22
+3.77
-0.03
+0.48
+0.51
0.00
+0.00
-0.00
0.00
+0.00
-0.00
+0.18
+0.19
-0.24
-0.24
+0.00
-0.07
-0.07
+0.00
-0.05
-0.05
+0.00
-0.07
-0.07
+0.00
-0.40
-0.40
+0.00

Upright Model Version 0.4.0
ESG Data Last Updated: March 29, 2022

Ad DTI
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Click here for the full story

About Upright's Net Impact Model

Upright Model

Upright's Net Impact Data quantifies the holistic value creation and impact of companies. It details both the negative and positive impacts a company has on the environment, health of people, society and knowledge, and forms a net sum of these costs and gains based on the economic costs of each impact category. The data is produced by Upright's Net Impact model, which is a mathematical model of the economy that produces continuously updated estimates of the net impact of companies by means of an information integration algorithm. The data is primarily sourced from the CORE open access database, which contains over 200 million scientific papers. Other sources of data include open databases published by the World Bank, IMF, WHO, OECD, IPCC, CDC and USDA.

Denali Therapeutics ESG Score - Frequently Asked Questions

How is Denali Therapeutics doing in terms of sustainability?

According to The Upright Project, which measures holistic value creation and impact of companies, Denali Therapeutics has a net impact ratio of 74.5%, indicating an overall positive sustainability impact. Denali Therapeutics seems to create the most significant positive value in the categories of Creating knowledge, Physical diseases, and Jobs. On the other hand, these positive outcomes are achieved by using resources or causing negative impacts in the categories of Scarce human capital, Physical diseases, and Waste. Learn more on the sustainability of Denali Therapeutics.


More ESG Stocks and Research Tools

Related Companies:
Stock Lists:
Sustainability Tools:
This page (NASDAQ:DNLI) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
Can't believe it's happening again
Manward Press
He Is Giving Away Bitcoin
Crypto Swap Profits
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
Biden’s $374B Giveaway Into This Sector
DTI
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
Options trading has suddenly become more reliable.
Eagle Publishing